Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-001 in Relapsed or Refractory Multiple Myeloma
NCT06594211Phase 1Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dimethylaminomicheliolide in multiple myeloma (MM), sponsored by Renji Hospital. Primary endpoints: Dose-limiting toxicity at 28 days and Adverse Events at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06594211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594211.